Functional Characterization of a Spectrum of Genetic Variants in a Family With Succinic Semialdehyde Dehydrogenase Deficiency
Preprint
- 4 April 2024
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Succinic semialdehyde dehydrogenase (SSADH) is a mitochondrial enzyme involved in the catabolism of the neurotransmitter γ-amino butyric acid. Pathogenic variants in the gene encoding this enzyme cause SSADH deficiency, a developmental disease manifesting as hypotonia, autism and epilepsy. SSADH deficiency patients usually have family-specific gene variants. Here, we describe a family exhibiting four different SSADH variants, Val90Ala, Cys93Phe, and His180Tyr/Asn255Asp (a double variant). We provide a structural and functional characterization of these variants and show that Cys93Phe and Asn255Asp are pathogenic variants that affect the stability of the SSADH protein. Due to impairment of the cofactor NAD+ binding, these variants show a highly reduced enzyme activity. However, Val90Ala and His180Tyr exhibit normal activity and expression. The His180Tyr/Asn255Asp variant exhibits a highly reduced activity as a recombinant species, is inactive and shows a very low expression in eukaryotic cells. A treatment with substances that support protein folding by either increasing chaperone protein expression or by chemical means was not capable of increasing the expression of the pathogenic variants of the SSADH deficiency patient. However, stabilization of the folding of pathogenic SSADH variants by other substances may provide a treatment option for this disease.Keywords
All Related Versions
This publication has 31 references indexed in Scilit:
- Phenotypic correlates of structural and functional protein impairments resultant from ALDH5A1 variantsHuman Genetics, 2023
- Development of precision therapies for rare inborn errors of metabolism: Functional investigations in cell culture modelsJournal of Inherited Metabolic Disease, 2023
- Efficacy and safety of arimoclomol in Niemann‐Pick disease type C: Results from a double‐blind, randomised, placebo‐controlled, multinational phase 2/3 trial of a novel treatmentJournal of Inherited Metabolic Disease, 2021
- Succinic semialdehyde dehydrogenase deficiency: The combination of a novel ALDH5A1 gene mutation and a missense SNP strongly affects SSADH enzyme activity and stabilityMolecular Genetics and Metabolism, 2018
- BindProfX: Assessing Mutation-Induced Binding Affinity Change by Protein Interface Profiles with Pseudo-CountsJournal of Molecular Biology, 2017
- Succinic semialdehyde dehydrogenase deficiency: Lessons from mice and menJournal of Inherited Metabolic Disease, 2009
- Chemical and Biological Approaches Synergize to Ameliorate Protein-Folding DiseasesCell, 2008
- Mutational spectrum of the succinate semialdehyde dehydrogenase (ALDH5A1) gene and functional analysis of 27 novel disease-causing mutations in patients with SSADH deficiencyHuman Mutation, 2003
- Succinic semialdehyde dehydrogenase deficiency: an inborn error of gamma-aminobutyric acid metabolismClinica Chimica Acta, 1983
- Urinary excretion of gamma-hydroxybutyric acid in a patient with neurological abnormalities. The probability of a new inborn error of metabolismClinica Chimica Acta, 1981